Return to all milestones


Viruses don't stand still. And neither do we. We're continuing to adapt and respond as COVID-19 evolves. Employees from across the innovative pharmaceutical industry - from scientists in the labs to engineers in the production facilities and medical experts on the ground - are applying their expertise, passion and creativity to find new and better solutions, so we can tackle emerging variants and be better prepared for the future.

The WHO is publishing a COVID Vaccine Tracker and Landscape document This link will open in a new window twice weekly. This provides summary tables of COVID-19 vaccine candidates, including analysis and visualization, progression through phased trials, and links to reports on safety and efficacy.

BIO has also created a weekly pipeline tracker This link will open in a new window to provide updates on clinical innovation happening in the industry to combat COVID-19.

The innovative pharmaceutical industry is developing new COVID-19 vaccines and adapting existing ones to offer longer, broader and more durable protection. This includes multi-valent vaccines that can offer protection against more than one variant of COVID-19.

The innovative pharmaceutical industry is developing new medicines to treat the symptoms of COVID-19 at every stage of infection, which could help relieve pressures on health systems, for example by reducing the risk of hospitalization. These include antiviral therapies which aim to stop the virus during the early stages of infection, prevent it from copying itself in our cells, or strengthen our body's existing viral defences.

In addition, we are developing therapies designed to protect people's heart, blood, and lungs from the harmful effects of COVID-19 infection, and medicines which aim to relieve the life-altering symptoms of long COVID.

100 Days Mission Industry Roundtable: IFPMA is pleased to be part of the re-launch of the 100 Days Mission and the Pact for Pandemic Readiness, sharing what we have learned from our experience in tackling COVID-19, what has worked and where we can do better next time. The innovative pharmaceutical industry looks forward to working with G7 and other stakeholders including CEPI, GAVI, WHO and the Bill & Melinda Gates Foundation and Wellcome Trust to reach the 100 Days Mission. 

In just two years, the innovative pharmaceutical industry has developed COVID-19 vaccines and treatments at record speed and in historic quantities:

  • 0

    vaccines authorized or approved by at least one country

  • 0

    approved therapeutics worldwide

  • 0

    manufacturing deals for COVID-19 vaccines

  • 0

    manufacturing deals for COVID-19 therapeutics

  • 0billion

    COVID-19 vaccines produced

Autumn 2022